top of page
Insights & News


Q3 2026 Private Bio/Pharma Funding: Activity Rebounds
Private bio/pharma funding activity rose sharply in Q3 2026 after a difficult first half. BiopharmIQ recorded approximately $15.33B across 365 funding events covering 349 companies. Both event counts and funding amounts exceeded Q2 2026 and Q3 2024 and 2025. Early-stage funding also improved from Q3 2025, although amounts remained below Q3 2024. Large debt and refinancing transactions contributed significantly to the overall funding total. Please note: In this report, funding
Oct 15


Bio/Pharma IPOs in Q3 2026: More Deals, Bigger Checks
Bio/pharma IPO activity increased in Q3 2026, with BPIQ recording 10 priced offerings, compared with seven in Q1 and eight in Q2. July brought three listings, August five, and September two. That puts 2026 at 25 IPOs through September, already above the full-year total for each year from 2022 through 2025. The Quarterly View Q3 was the busiest quarter since 2021 in BPIQ’s dataset. Still, its 10 IPOs were well below the 25 recorded in Q3 2021. Activity is recovering, but the m
Oct 15


Bio/pharma IPO Market Selectively Opens in H1 2026
The bio/pharma IPO market reopened in H1 2026, as we predicted based on the bullish public bio/pharma market starting in the 2nd half of 2025. However, the bio/pharma IPO activity remains far below its historical peak in 2020/2021. BPIQ recorded 15 IPOs in H1 2026, up 114% from seven in H1 2025. This was the highest first-half total since 2021, but only narrowly above the 14 IPOs recorded in H1 2022 and still far below the 61 recorded in H1 2021. Quarterly Activity Shows a Gr
Jul 16


H1 2026 Private Bio/Pharma Funding: Environment Remained Challenging
H1 2026 private bio/pharma funding reached its highest total amount invested of the past three years, but the number of funding events declined by almost 33%. Total capital increased slightly compared with H1 2024 and H1 2025, while funding activity remained well below prior-year levels. This points to an investment environment where capital is still available, but fewer companies are securing it. In total, private companies raised approximately $20.3B across 366 funding even
Jul 15


Q1 2026 Bio/Pharma Private Funding Remains Difficult, But Stage Is Set for a Rebound
Q1 2026 private biotech funding remains low and did not match the January-driven peak seen in early 2025, but overall capital deployment remained broadly comparable. Unlike Q1 2025’s front-loaded start, funding in Q1 2026 was more evenly distributed across the quarter, pointing to a more stable, though still selective, investment environment. We still believe the stage is set for a rebound in private biotech funding starting in the 2nd half of 2026. In total, private companie
Apr 20


2025 Full-Year Bio/Pharma Private Funding Trends
Private bio/pharma funding in 2025 totaled approximately $40.0 B across 1,045 private funding events, slightly below 2024’s $40.4 B , but substantially below 2024’s 1,367 deals (FN1). Activity was heavily front-loaded, with January 2025 alone accounting for $6.3 B and 138 deals , the single most active month of the year. After a mid-year lull in deal volume and capital deployment, the market saw modest late-year momentum, particularly in October ($6.0 B) and December ($3
Feb 3


Why 2026 Could Be a Breakout Year for Private Biotech Funding
After a difficult 3 years of private biotech funding for early-stage biotech companies (FN1, FN2), we predict that 2026 will be a breakout year. Why? Public smid-cap biotech stocks soared in the 2nd half of 2025; Historical data shows that when public smid-cap biotech stocks soar, the biotech IPO market opens up the following year; Once the biotech IPO market opens, private funding should follow in subsequent quarters Public smid-cap biotech stocks soared in the 2nd half of 2
Jan 29
Get the latest DHL news and life science patent and investor insights right in your mailbox!
bottom of page
